1 Introduction The escalating prevalence of obesity and type 2 diabetes (T2D) has resulted in significant disability, exorbitant complications and even reduced life expectancy ( Obesity is the strongest risk factor for T2D as it causes insulin resistance, a key driver in development of T2D ( Given the strong association between obesity and T2D, weight loss in people with T2D may have favourable effects on glycaemic control, insulin sensitivity and cardiovascular-metabolic comorbidities ( In recent years, glucagon-like peptide-1 receptor analogues (GLP-1 RAs) has revolutionised the treatment of T2D, as they have shown remarkable efficacy in reducing blood glucose levels while promoting substantial weight loss and weight maintenance, allowing for improved disease management ( Glucose-dependent insulinotropic polypeptide (GIP) is the other major incretin hormone ( Tirzepatide, a novel dual agonist of GIP and GLP-1 receptors, is currently undergoing development for the management of T2D and obesity ( To date, only one systematic review and meta-analysis has examined the association between tirzepatide and pancreatitis and cholelithiasis, and its results were limited to cholelithiasis and did not include other biliary or gallbladder diseases such as cholecystitis and cholangitis
Phagocytes recognize and combine with apoptotic cells through phagocytic receptors, that is, Eat me signals are transmitted into phagocytes, which leads to actin polymerization, cytoskeleton rearrangement, and phagocytes extend pseudopodes along the surface of apoptotic cells, which gradually extend to wrap apoptotic cells, and finally fuse to form phagocytes (Zhou and Yu, 2008)
A significant change in urine output or extreme dizziness
Its normal for the first two cycles of injections not to offer as much relief
